Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean glycol lactate and lactate acid?
Displaying drugs 2176 - 2200 of 15242 in total

Margetuximab

The HER2 oncoprotein, the product of the human ERBB2/mouse neu genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by ERBB2 overexpression, a higher grade, a more...
Approved
Investigational
Matched Description: … breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and ... IgG1κ monoclonal antibody derived from the same mouse 4D5 clone that [trastuzumab] is derived from and ... , A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Teniposide

Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic...
Approved
Matched Description: … Teniposide acts primarily in the G2 and S phases of the cycle. ... Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. ... This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Dydrogesterone

A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.
Approved
Investigational
Withdrawn
Matched Description: … Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does …
Matched Categories: … dydrogesterone and estrogen ... dydrogesterone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …

Halcinonide

Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of...
Approved
Investigational
Withdrawn
Matched Description: … of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. ... Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations …

Nomegestrol

Nomegestrol is an ingredient in the EMA-authorised product Zoely.
Approved
Matched Categories: … nomegestrol and estrogen ... nomegestrol and estradiol ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …

Clobetasol

Clobetasol is under investigation for the treatment of Scleroderma. Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids.
Approved
Experimental
Investigational
Matched Description: … Clobetasol has been investigated for the prevention of Psoriasis and Cutaneous Atrophy Due to Corticosteroids …
Matched Categories: … clobetasol and antibiotics ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Binimetinib

Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib.[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of Encorafenib and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients...
Approved
Investigational
Matched Description: … ] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with ... Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase ... [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Xamoterol

Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Approved
Matched Description: … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function …

Dexrazoxane

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and...
Approved
Withdrawn
Matched Description: … prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. ... [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the …

NADH

NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by...
Approved
Nutraceutical
Matched Iupac: … [(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid …
Matched Description: … electron carrier by being alternately oxidized (NAD+) and reduced (NADH). ... It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an ... NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide …
Matched Categories: … Enzymes and Coenzymes ... Nucleic Acids, Nucleotides, and Nucleosides …

Alatrofloxacin

Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid …

Cefamandole nafate

Approved
Matched Iupac: … methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …

Carboprost tromethamine

A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Approved
Matched Iupac: … -7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hept-5-enoic acid …
Matched Description: … A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy …
Matched Categories: … Genito Urinary System and Sex Hormones …

Somatrem

Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short...
Approved
Investigational
Withdrawn
Matched Description: … Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Magnesium glycinate

Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
Approved

Cladribine

Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia....
Approved
Investigational
Matched Description: … Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and ... [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …

Colistin

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Approved
Matched Description: … It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Lomustine

An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Description: … An alkylating agent of value against both hematologic malignancies and solid tumors. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Bucetin

Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.
Approved
Withdrawn
Matched Description: … Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn …

Elivaldogene autotemcel

Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy, an X-linked genetic disorder characterized by missing or non-functional ABCD1 gene that codes for ALDP. ALDP is a key protein that normally...
Approved
Matched Description: … destruction of myelin, which is an insulating layer and essential component of nerves. ... Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and ... It was approved by the European Commission in July 2021 under the market name Skysona, and was later …
Matched Categories: … Cellular and Gene Therapy ... Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Tesamorelin

Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Approved
Investigational
Matched Description: … Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Quinagolide

Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis . Newer dopamine receptor agonists such as quinagolide and DB00248 are...
Approved
Investigational
Matched Description: … Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido ... Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the ... It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand …
Matched Categories: … Genito Urinary System and Sex Hormones …

Salmon calcitonin

Synthetic peptide, 32 residues long formulated as a nasal spray.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Parathyroid Hormones and Analogues ... Calcium-Regulating Hormones and Agents ... Parathyroid and Antiparathyroid Agents …

Cerliponase alfa

Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl...
Approved
Investigational
Matched Description: … treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Relatlimab

Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying drugs 2176 - 2200 of 15242 in total